{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:36Z","timestamp":1787020116867,"version":"build-2736575974"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100019736","name":"Farmer Family Foundation","doi-asserted-by":"publisher","award":["234-052"],"award-info":[{"award-number":["234-052"]}],"id":[{"id":"10.13039\/100019736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019736","name":"Farmer Family Foundation","doi-asserted-by":"publisher","award":["234-052"],"award-info":[{"award-number":["234-052"]}],"id":[{"id":"10.13039\/100019736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019736","name":"Farmer Family Foundation","doi-asserted-by":"publisher","award":["234-052"],"award-info":[{"award-number":["234-052"]}],"id":[{"id":"10.13039\/100019736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019736","name":"Farmer Family Foundation","doi-asserted-by":"publisher","award":["234-052"],"award-info":[{"award-number":["234-052"]}],"id":[{"id":"10.13039\/100019736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019736","name":"Farmer Family Foundation","doi-asserted-by":"publisher","award":["234-052"],"award-info":[{"award-number":["234-052"]}],"id":[{"id":"10.13039\/100019736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019736","name":"Farmer Family Foundation","doi-asserted-by":"publisher","award":["234-052"],"award-info":[{"award-number":["234-052"]}],"id":[{"id":"10.13039\/100019736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS1100879"],"award-info":[{"award-number":["R01 NS1100879"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS1100879"],"award-info":[{"award-number":["R01 NS1100879"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS1100879"],"award-info":[{"award-number":["R01 NS1100879"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS1100879"],"award-info":[{"award-number":["R01 NS1100879"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jane & Alan Batkin Research Fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurosci"],"DOI":"10.1186\/s12868-025-00939-7","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T04:41:48Z","timestamp":1741063308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Short-term lipopolysaccharide treatment leads to astrocyte activation in LRRK2 G2019S knock-in mice without loss of dopaminergic neurons"],"prefix":"10.1186","volume":"26","author":[{"given":"Hoang Kieu Chi","family":"Ngo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akriti","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Ayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace F.","family":"Crotty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Schwarzschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachit","family":"Bakshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"939_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41531-020-0110-8","volume":"6","author":"J Tran","year":"2020","unstructured":"Tran J, Anastacio H, Bardy C. Genetic predispositions of Parkinson\u2019s disease revealed in patient-derived brain cells. NPJ Parkinsons Dis. 2020;6:8.","journal-title":"NPJ Parkinsons Dis"},{"key":"939_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","volume":"19","author":"MA Blauwendraat","year":"2020","unstructured":"Blauwendraat MA, Nalls AB, Singleton. The genetic architecture of Parkinson\u2019s disease. Lancet Neurol. 2020;19:170\u20138.","journal-title":"Lancet Neurol"},{"key":"939_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/jnc.14902","volume":"152","author":"L Correia Guedes","year":"2020","unstructured":"Correia Guedes L, Mestre T, Outeiro TF, Ferreira JJ. Are genetic and idiopathic forms of Parkinson\u2019s disease the same disease? J Neurochem. 2020;152:515\u201322.","journal-title":"J Neurochem"},{"key":"939_CR4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1097\/GIM.0b013e31815bf97c","volume":"9","author":"N Pankratz","year":"2007","unstructured":"Pankratz N, Foroud T. Genetics of Parkinson disease. Genet Med. 2007;9:801\u201311.","journal-title":"Genet Med"},{"key":"939_CR5","doi-asserted-by":"crossref","unstructured":"Usmani F, Shavarebi A, Hiniker. The Cell Biology of LRRK2 in Parkinson\u2019s Disease. Mol Cell Biol, (2021).","DOI":"10.1128\/MCB.00660-20"},{"key":"939_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.tins.2006.03.006","volume":"29","author":"WJ Mata","year":"2006","unstructured":"Mata WJ, Wedemeyer MJ, Farrer JP, Taylor KA, Gallo. LRRK2 in Parkinson\u2019s disease: protein domains and functional insights. Trends Neurosci. 2006;29:286\u201393.","journal-title":"Trends Neurosci"},{"key":"939_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1126\/science.aar5683","volume":"360","author":"DR Alessi","year":"2018","unstructured":"Alessi DR, Sammler E. LRRK2 kinase in Parkinson\u2019s disease. Science. 2018;360:36\u20137.","journal-title":"Science"},{"key":"939_CR8","doi-asserted-by":"crossref","unstructured":"Di Maio R et al. LRRK2 activation in idiopathic Parkinson\u2019s disease. Sci Transl Med 10, (2018).","DOI":"10.1126\/scitranslmed.aar5429"},{"key":"939_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ceb.2020.01.001","volume":"63","author":"M Taylor","year":"2020","unstructured":"Taylor M, Alessi DR. Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson\u2019s disease. Curr Opin Cell Biol. 2020;63:102\u201313.","journal-title":"Curr Opin Cell Biol"},{"key":"939_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1042\/BST20160238","volume":"45","author":"M Volta","year":"2017","unstructured":"Volta M, Melrose H. LRRK2 mouse models: dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis. Biochem Soc Trans. 2017;45:113\u201322.","journal-title":"Biochem Soc Trans"},{"key":"939_CR11","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3389\/fnins.2020.00674","volume":"14","author":"SP Seegobin","year":"2020","unstructured":"Seegobin SP, et al. Progress in LRRK2-Associated Parkinson\u2019s disease animal models. Front Neurosci. 2020;14:674.","journal-title":"Front Neurosci"},{"key":"939_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/ana.25436","volume":"85","author":"R Bakshi","year":"2019","unstructured":"Bakshi R, et al. Higher urate in LRRK2 mutation carriers resistant to Parkinson disease. Ann Neurol. 2019;85:593\u20139.","journal-title":"Ann Neurol"},{"key":"939_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.tins.2017.04.001","volume":"40","author":"HDE Booth","year":"2017","unstructured":"Booth HDE, Hirst WD, Wade-Martins R. The role of astrocyte dysfunction in Parkinson\u2019s disease pathogenesis. Trends Neurosci. 2017;40:358\u201370.","journal-title":"Trends Neurosci"},{"key":"939_CR14","doi-asserted-by":"crossref","unstructured":"Kim C et al. LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. Sci Transl Med 12, (2020).","DOI":"10.1126\/scitranslmed.aay0399"},{"key":"939_CR15","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.it.2016.08.001","volume":"37","author":"A Schwartz","year":"2016","unstructured":"Schwartz A, Deczkowska. Neurological disease as a failure of Brain-Immune crosstalk: the multiple faces of neuroinflammation. Trends Immunol. 2016;37:668\u201379.","journal-title":"Trends Immunol"},{"key":"939_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.tcb.2013.08.004","volume":"24","author":"C Kyritsis","year":"2014","unstructured":"Kyritsis C, Kizil M, Brand. Neuroinflammation and central nervous system regeneration in vertebrates. Trends Cell Biol. 2014;24:128\u201335.","journal-title":"Trends Cell Biol"},{"key":"939_CR17","doi-asserted-by":"publisher","first-page":"105028","DOI":"10.1016\/j.nbd.2020.105028","volume":"144","author":"TI Kam","year":"2020","unstructured":"Kam TI, Hinkle JT, Dawson TM, Dawson VL. Microglia and astrocyte dysfunction in Parkinson\u2019s disease. Neurobiol Dis. 2020;144:105028.","journal-title":"Neurobiol Dis"},{"key":"939_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","volume":"21","author":"Gerhard","year":"2006","unstructured":"Gerhard, et al. In vivo imaging of microglial activation with [11\u00a0C](R)-PK11195 PET in idiopathic Parkinson\u2019s disease. Neurobiol Dis. 2006;21:404\u201312.","journal-title":"Neurobiol Dis"},{"key":"939_CR19","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","volume":"24","author":"SP Yun","year":"2018","unstructured":"Yun SP, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease. Nat Med. 2018;24:931\u20138.","journal-title":"Nat Med"},{"key":"939_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/glia.20467","volume":"55","author":"L Qin","year":"2007","unstructured":"Qin L, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007;55:453\u201362.","journal-title":"Glia"},{"key":"939_CR21","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/brain\/awy077","volume":"141","author":"E Kozina","year":"2018","unstructured":"Kozina E, et al. Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo. Brain. 2018;141:1753\u201369.","journal-title":"Brain"},{"key":"939_CR22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.nbd.2015.02.031","volume":"78","author":"M Yue","year":"2015","unstructured":"Yue M, et al. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis. 2015;78:172\u201395.","journal-title":"Neurobiol Dis"},{"key":"939_CR23","doi-asserted-by":"crossref","unstructured":"Crotty GF et al. Association of caffeine and related analytes with resistance to Parkinson\u2019s disease among LRRK2 mutation carriers: A metabolomic study. Neurology, (2020).","DOI":"10.1212\/WNL.0000000000010863"},{"key":"939_CR24","unstructured":"National Research Council, Guide for the Care and Use of Laboratory Animals, 8th edition. (The National Academies Press, 2011)."},{"key":"939_CR25","doi-asserted-by":"crossref","unstructured":"N. Percie du Sert et al., The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol 18, e3000410 (2020).","DOI":"10.1371\/journal.pbio.3000410"},{"key":"939_CR26","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.neuroscience.2009.04.031","volume":"161","author":"ZC Baquet","year":"2009","unstructured":"Baquet ZC, Williams D, Brody J, Smeyne RJ. A comparison of model-based (2D) and design-based (3D) Stereological methods for estimating cell number in the substantia Nigra Pars compacta (SNpc) of the C57BL\/6J mouse. Neuroscience. 2009;161:1082\u201390.","journal-title":"Neuroscience"},{"key":"939_CR27","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1523\/JNEUROSCI.3457-15.2016","volume":"36","author":"CC Hung","year":"2016","unstructured":"Hung CC, et al. Astrocytic GAP43 induced by the TLR4\/NF-kappaB\/STAT3 Axis attenuates Astrogliosis-Mediated microglial activation and neurotoxicity. J Neurosci. 2016;36:2027\u201343.","journal-title":"J Neurosci"},{"key":"939_CR28","doi-asserted-by":"publisher","first-page":"RC143","DOI":"10.1523\/JNEUROSCI.21-10-j0001.2001","volume":"21","author":"F Chen","year":"2001","unstructured":"Chen F, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson\u2019s disease. J Neurosci. 2001;21:RC143.","journal-title":"J Neurosci"},{"key":"939_CR29","doi-asserted-by":"crossref","unstructured":"Schepici G, Silvestro S, Bramanti P, Mazzon E. Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson\u2019s Disease. Int J Mol Sci 21, (2020).","DOI":"10.3390\/ijms21134766"},{"key":"939_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12974-020-1728-5","volume":"17","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, et al. A novel role of NLRP3-generated IL-1beta in the acute-chronic transition of peripheral lipopolysaccharide-elicited neuroinflammation: implications for sepsis-associated neurodegeneration. J Neuroinflammation. 2020;17:64.","journal-title":"J Neuroinflammation"},{"key":"939_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1742-2094-5-37","volume":"5","author":"W Lee","year":"2008","unstructured":"Lee W, et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation. 2008;5:37.","journal-title":"J Neuroinflammation"},{"key":"939_CR32","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.nbd.2006.04.001","volume":"23","author":"E Greggio","year":"2006","unstructured":"Greggio E, et al. Kinase activity is required for the toxic effects of mutant LRRK2\/dardarin. Neurobiol Dis. 2006;23:329\u201341.","journal-title":"Neurobiol Dis"},{"key":"939_CR33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/hmg\/ddl471","volume":"16","author":"West","year":"2007","unstructured":"West, et al. Parkinson\u2019s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet. 2007;16:223\u201332.","journal-title":"Hum Mol Genet"},{"key":"939_CR34","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/1570159X13666151030102847","volume":"14","author":"JM Taymans","year":"2016","unstructured":"Taymans JM, Greggio E. LRRK2 kinase Inhibition as a therapeutic strategy for Parkinson\u2019s disease, where do we stand?? Curr Neuropharmacol. 2016;14:214\u201325.","journal-title":"Curr Neuropharmacol"},{"key":"939_CR35","doi-asserted-by":"publisher","first-page":"164ra161","DOI":"10.1126\/scitranslmed.3004485","volume":"4","author":"Z Sheng","year":"2012","unstructured":"Sheng Z, et al. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Transl Med. 2012;4:164ra161.","journal-title":"Sci Transl Med"},{"key":"939_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41531-018-0049-1","volume":"4","author":"JH Kluss","year":"2018","unstructured":"Kluss JH, et al. Detection of endogenous S1292 LRRK2 autophosphorylation in mouse tissue as a readout for kinase activity. NPJ Parkinsons Dis. 2018;4:13.","journal-title":"NPJ Parkinsons Dis"},{"issue":"Suppl 3","key":"939_CR37","doi-asserted-by":"publisher","first-page":"S548","DOI":"10.1002\/mds.22062","volume":"23","author":"JA Obeso","year":"2008","unstructured":"Obeso JA, et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson\u2019s disease. Mov Disord. 2008;23(Suppl 3):S548\u2013559.","journal-title":"Mov Disord"},{"key":"939_CR38","doi-asserted-by":"crossref","unstructured":"Steger et al. Phosphoproteomics reveals that Parkinson\u2019s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife 5, (2016).","DOI":"10.7554\/eLife.12813"},{"issue":"9","key":"939_CR39","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3390\/biom11091361","volume":"11","author":"AM Jurga","year":"2021","unstructured":"Jurga AM, Paleczna M, Kadluczka J, Kuter KZ. Beyond the GFAP-Astrocyte protein markers in the brain. Biomolecules. 2021;11(9):1361.","journal-title":"Biomolecules"},{"key":"939_CR40","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.expneurol.2010.02.007","volume":"223","author":"MC Kachroo","year":"2010","unstructured":"Kachroo MC, Irizarry MA, Schwarzschild. Caffeine protects against combined Paraquat and maneb-induced dopaminergic neuron degeneration. Exp Neurol. 2010;223:657\u201361.","journal-title":"Exp Neurol"},{"key":"939_CR41","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.neuroscience.2016.02.035","volume":"322","author":"K Xu","year":"2016","unstructured":"Xu K, et al. Neuroprotection by caffeine in the MPTP model of Parkinson\u2019s disease and its dependence on adenosine A2A receptors. Neuroscience. 2016;322:129\u201337.","journal-title":"Neuroscience"},{"key":"939_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","volume":"16","author":"E Tolosa","year":"2020","unstructured":"Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol. 2020;16:97\u2013107.","journal-title":"Nat Rev Neurol"},{"key":"939_CR43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/978-3-319-49969-7_9","volume":"14","author":"Y Xiong","year":"2017","unstructured":"Xiong Y, Dawson TM, Dawson VL. Models of LRRK2-Associated Parkinson\u2019s disease. Adv Neurobiol. 2017;14:163\u201391.","journal-title":"Adv Neurobiol"},{"key":"939_CR44","doi-asserted-by":"publisher","first-page":"e18568","DOI":"10.1371\/journal.pone.0018568","volume":"6","author":"D Ramonet","year":"2011","unstructured":"Ramonet D, et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in Transgenic mice expressing G2019S mutant LRRK2. PLoS ONE. 2011;6:e18568.","journal-title":"PLoS ONE"},{"key":"939_CR45","doi-asserted-by":"crossref","unstructured":"Chen CY et al. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ 19, 1623\u20131633 (2012).","DOI":"10.1038\/cdd.2012.42"},{"key":"939_CR46","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1073\/pnas.1712648115","volume":"115","author":"Y Xiong","year":"2018","unstructured":"Xiong Y, et al. Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S Transgenic mice. Proc Natl Acad Sci U S A. 2018;115:1635\u201340.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"939_CR47","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jchemneu.2016.01.007","volume":"76","author":"SS Karuppagounder","year":"2016","unstructured":"Karuppagounder SS, et al. LRRK2 G2019S Transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity. J Chem Neuroanat. 2016;76:90\u20137.","journal-title":"J Chem Neuroanat"},{"key":"939_CR48","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/hmg\/ddz271","volume":"29","author":"Arbez","year":"2020","unstructured":"Arbez, et al. G2019S-LRRK2 mutation enhances MPTP-linked parkinsonism in mice. Hum Mol Genet. 2020;29:580\u201390.","journal-title":"Hum Mol Genet"},{"key":"939_CR49","doi-asserted-by":"publisher","first-page":"7128","DOI":"10.1523\/JNEUROSCI.3314-15.2016","volume":"36","author":"BA Matikainen-Ankney","year":"2016","unstructured":"Matikainen-Ankney BA, et al. Altered development of synapse structure and function in striatum caused by Parkinson\u2019s Disease-Linked LRRK2-G2019S mutation. J Neurosci. 2016;36:7128\u201341.","journal-title":"J Neurosci"},{"key":"939_CR50","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1093\/hmg\/ddr348","volume":"20","author":"C Herzig","year":"2011","unstructured":"Herzig C, et al. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet. 2011;20:4209\u201323.","journal-title":"Hum Mol Genet"},{"key":"939_CR51","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3389\/fneur.2018.00860","volume":"9","author":"A Troncoso-Escudero","year":"2018","unstructured":"Troncoso-Escudero A, Parra M, Nassif RL, Vidal O. Unraveling the role of neuroinflammation in the progression of Parkinson\u2019s disease. Front Neurol. 2018;9:860.","journal-title":"Front Neurol"},{"key":"939_CR52","doi-asserted-by":"crossref","unstructured":"Ryan KJ et al. A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants. Sci Transl Med 9, (2017).","DOI":"10.1126\/scitranslmed.aai7635"},{"key":"939_CR53","doi-asserted-by":"publisher","first-page":"e0210248","DOI":"10.1371\/journal.pone.0210248","volume":"14","author":"J Kim","year":"2019","unstructured":"Kim J, et al. LRRK2 kinase plays a critical role in manganese-induced inflammation and apoptosis in microglia. PLoS ONE. 2019;14:e0210248.","journal-title":"PLoS ONE"},{"key":"939_CR54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13024-021-00509-5","volume":"17","author":"E Xu","year":"2022","unstructured":"Xu E, et al. Pathological alpha-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain. Mol Neurodegener. 2022;17:7.","journal-title":"Mol Neurodegener"},{"key":"939_CR55","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.it.2016.06.006","volume":"37","author":"E Colombo","year":"2016","unstructured":"Colombo E, Farina C. Astrocytes: key regulators of neuroinflammation. Trends Immunol. 2016;37:608\u201320.","journal-title":"Trends Immunol"},{"key":"939_CR56","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.it.2020.07.007","volume":"41","author":"F Giovannoni","year":"2020","unstructured":"Giovannoni F, Quintana FJ. The role of astrocytes in CNS inflammation. Trends Immunol. 2020;41:805\u201319.","journal-title":"Trends Immunol"},{"key":"939_CR57","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuron.2020.08.012","volume":"108","author":"M Linnerbauer","year":"2020","unstructured":"Linnerbauer M, Wheeler MA, Quintana FJ. Astrocyte crosstalk in CNS inflammation. Neuron. 2020;108:608\u201322.","journal-title":"Neuron"},{"key":"939_CR58","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41593-018-0325-8","volume":"22","author":"M Santello","year":"2019","unstructured":"Santello M, Toni N, Volterra A. Astrocyte function from information processing to cognition and cognitive impairment. Nat Neurosci. 2019;22:154\u201366.","journal-title":"Nat Neurosci"},{"key":"939_CR59","doi-asserted-by":"publisher","first-page":"14474","DOI":"10.1038\/s41598-020-71329-8","volume":"10","author":"TM Sonninen","year":"2020","unstructured":"Sonninen TM, et al. Metabolic alterations in Parkinson\u2019s disease astrocytes. Sci Rep. 2020;10:14474.","journal-title":"Sci Rep"},{"key":"939_CR60","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41531-021-00175-w","volume":"7","author":"Ramos-Gonzalez","year":"2021","unstructured":"Ramos-Gonzalez, et al. Astrocytic atrophy as a pathological feature of Parkinson\u2019s disease with LRRK2 mutation. NPJ Parkinsons Dis. 2021;7:31.","journal-title":"NPJ Parkinsons Dis"},{"key":"939_CR61","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1212\/WNL.0000000000004888","volume":"90","author":"M Fujimaki","year":"2018","unstructured":"Fujimaki M, et al. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology. 2018;90:e404\u201311.","journal-title":"Neurology"},{"key":"939_CR62","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1001\/jama.283.20.2674","volume":"283","author":"GW Ross","year":"2000","unstructured":"Ross GW, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000;283:2674\u20139.","journal-title":"JAMA"},{"key":"939_CR63","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/ana.1052","volume":"50","author":"Ascherio","year":"2001","unstructured":"Ascherio, et al. Prospective study of caffeine consumption and risk of Parkinson\u2019s disease in men and women. Ann Neurol. 2001;50:56\u201363.","journal-title":"Ann Neurol"},{"key":"939_CR64","doi-asserted-by":"publisher","first-page":"36040","DOI":"10.1074\/jbc.M206830200","volume":"277","author":"JF Chen","year":"2002","unstructured":"Chen JF, et al. 8-(3-Chlorostyryl)caffeine May attenuate MPTP neurotoxicity through dual actions of monoamine oxidase Inhibition and A2A receptor antagonism. J Biol Chem. 2002;277:36040\u20134.","journal-title":"J Biol Chem"},{"key":"939_CR65","doi-asserted-by":"publisher","first-page":"E12053","DOI":"10.1073\/pnas.1813365115","volume":"115","author":"Yan","year":"2018","unstructured":"Yan, et al. Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson\u2019s disease and DLB. Proc Natl Acad Sci U S A. 2018;115:E12053\u201362.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"939_CR66","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3389\/fphar.2017.00985","volume":"8","author":"CA Ballesteros-Yanez","year":"2017","unstructured":"Ballesteros-Yanez CA, Castillo S, Merighi S, Gessi. The role of adenosine receptors in psychostimulant addiction. Front Pharmacol. 2017;8:985.","journal-title":"Front Pharmacol"},{"key":"939_CR67","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/j.1471-4159.2006.03919.x","volume":"98","author":"M Taymans","year":"2006","unstructured":"Taymans M, Van den Haute C, Baekelandt V. Distribution of PINK1 and LRRK2 in rat and mouse brain. J Neurochem. 2006;98:951\u201361.","journal-title":"J Neurochem"},{"key":"939_CR68","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1471-4159.2006.04246.x","volume":"100","author":"Higashi","year":"2007","unstructured":"Higashi, et al. Expression and localization of Parkinson\u2019s disease-associated leucine-rich repeat kinase 2 in the mouse brain. J Neurochem. 2007;100:368\u201381.","journal-title":"J Neurochem"},{"key":"939_CR69","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.tins.2006.09.004","volume":"29","author":"MA Schwarzschild","year":"2006","unstructured":"Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson\u2019s disease. Trends Neurosci. 2006;29:647\u201354.","journal-title":"Trends Neurosci"},{"key":"939_CR70","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nn.3636","volume":"17","author":"Parisiadou","year":"2014","unstructured":"Parisiadou, et al. LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. Nat Neurosci. 2014;17:367\u201376.","journal-title":"Nat Neurosci"}],"container-title":["BMC Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12868-025-00939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12868-025-00939-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12868-025-00939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T04:42:00Z","timestamp":1741063320000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurosci.biomedcentral.com\/articles\/10.1186\/s12868-025-00939-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["939"],"URL":"https:\/\/doi.org\/10.1186\/s12868-025-00939-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4076333\/v1","asserted-by":"object"}]},"ISSN":["1471-2202"],"issn-type":[{"value":"1471-2202","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"11 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the MGH Institutional Animal Care and Use Committee under the National Institutes of Health\u2019s Guidelines for the Care and Use of Laboratory Animals [\n                      \n                      ] (approval number: 2006N000120).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"19"}}